[go: up one dir, main page]

FI963028L - RZR-reseptoriperheen avulla suoritettava seulontamenetelmä - Google Patents

RZR-reseptoriperheen avulla suoritettava seulontamenetelmä Download PDF

Info

Publication number
FI963028L
FI963028L FI963028A FI963028A FI963028L FI 963028 L FI963028 L FI 963028L FI 963028 A FI963028 A FI 963028A FI 963028 A FI963028 A FI 963028A FI 963028 L FI963028 L FI 963028L
Authority
FI
Finland
Prior art keywords
rzr
screening method
receptor family
receptor
family
Prior art date
Application number
FI963028A
Other languages
English (en)
Swedish (sv)
Other versions
FI963028A7 (fi
FI963028A0 (fi
Inventor
Irmgard Wiesenberg
Martin Missbach
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI963028A0 publication Critical patent/FI963028A0/fi
Publication of FI963028A7 publication Critical patent/FI963028A7/fi
Publication of FI963028L publication Critical patent/FI963028L/fi

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
FI963028A 1994-03-30 1995-03-18 RZR-reseptoriperheen avulla suoritettava seulontamenetelmä FI963028L (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94810196 1994-03-30
PCT/EP1995/001017 WO1995027202A1 (en) 1994-03-30 1995-03-18 Screening method using the rzr receptor family

Publications (3)

Publication Number Publication Date
FI963028A0 FI963028A0 (fi) 1996-07-31
FI963028A7 FI963028A7 (fi) 1996-09-27
FI963028L true FI963028L (fi) 1996-09-27

Family

ID=8218235

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963028A FI963028L (fi) 1994-03-30 1995-03-18 RZR-reseptoriperheen avulla suoritettava seulontamenetelmä

Country Status (8)

Country Link
US (2) US5958683A (fi)
EP (1) EP0753147A1 (fi)
JP (1) JPH09511334A (fi)
AU (1) AU2109695A (fi)
CA (1) CA2182700A1 (fi)
FI (1) FI963028L (fi)
HU (1) HUT75128A (fi)
WO (1) WO1995027202A1 (fi)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2746313B1 (fr) * 1996-03-22 1998-04-17 Adir Utilisation de la melatonine et des ligands melatoninergiques pour l'obtention de compositions pharmaceutiques destinees a la prevention et au traitement du diabete et des complications diabetiques
EP0835660A1 (en) * 1996-10-14 1998-04-15 Gaston Edmond Filomena Merckx Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions
FR2776388B1 (fr) * 1998-03-20 2006-04-28 Lipha Utilisation de recepteurs de la famille ror pour le criblage de substances utiles pour le traitement de l'atherosclerose
WO1999062507A1 (en) 1998-06-02 1999-12-09 Arthromics Plc Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease
GB9924057D0 (en) * 1999-10-11 1999-12-15 Novartis Ag Organic compounds
FR2813315B1 (fr) * 2000-08-23 2002-10-18 Genfit S A Procede d'identification de substances utiles pour le traitement de l'inflammation mettant en oeuvre l'element de reponse du recepteur ror du gene ikbalpha
WO2003091700A2 (en) * 2002-03-26 2003-11-06 Centocor, Inc. Epitope mapping using nuclear magnetic resonance
US20050165218A1 (en) * 2002-04-29 2005-07-28 Rene Beerli Crystal structure of the ligand binding domain of the retinoic acid-related orphan receptor alpha (ror-alpha)
WO2004047855A2 (en) * 2002-11-27 2004-06-10 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Proteins involved in the regulation of energy homeostasis
AU2003302741A1 (en) * 2002-12-10 2004-06-30 The Regents Of The University Of California A method for creating nuclear receptor activity modulating pharmaceuticals
US20050186138A1 (en) * 2003-10-16 2005-08-25 Irm, Llc Methods and compositions for modulating circadian rhythm
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
WO2014026329A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH459216A (de) * 1965-10-29 1968-07-15 Geigy Ag J R Verfahren zur Herstellung von neuen Azinen
CH511877A (de) * 1969-07-17 1971-08-31 Ciba Geigy Ag Verfahren zur Herstellung eines neuen Thiosemicarbazons
DE2632747A1 (de) * 1975-08-06 1977-02-24 Ciba Geigy Ag Azine von sechs- und siebengliedrigen thiazaheterocyclen
EP0085275B1 (de) * 1982-01-22 1986-02-19 Ciba-Geigy Ag Substituierte Thiazolidinylester von Mineralsäuren
US4771056A (en) * 1985-08-29 1988-09-13 Roman Rozencwaig Method of medical treatment with serotonin antagonists
US5283343A (en) * 1987-08-17 1994-02-01 Whitby Research, Inc. 2-aryl substituted N-acetyltryptamines and process of preparing such
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5151446A (en) * 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
US6492137B1 (en) * 1989-11-16 2002-12-10 The Salk Institute For Biological Studies Response element compositions and assays employing same
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE69115221T2 (de) * 1990-09-28 1996-08-22 I F L O S A S Di Giorgio E Ald Methode zur Synthese eines Präparats zur Regulation der Empfängnis und des Menstruationszyklus mit onkostatischen antikinetosischen, preventiven und therapeutischen Eigenschaften zur Behandlung von Brustkrebs und Melanomen.
US5177091A (en) * 1990-12-06 1993-01-05 Ciba-Geigy Corporation Use of carbazones as novel active ingredients in medicaments
JPH06508507A (ja) * 1991-03-18 1994-09-29 ザ　ソールク　インスチチュート　フォア　バイオロジカル　スタディズ 受容体認識配列組成物およびこれを用いた分析法
FR2674524B1 (fr) * 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
AU658175B2 (en) * 1991-04-12 1995-04-06 Novartis Ag Use of 2-iminothiazolidin-4-one derivatives as novel pharmaceutical active ingredients
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680507B1 (fr) * 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5206377A (en) * 1991-12-05 1993-04-27 Whitby Research, Inc. Compounds useful as antiproliferative agents
EP0548017A1 (de) * 1991-12-18 1993-06-23 Ciba-Geigy Ag Neue Thiazole
TW211005B (fi) * 1991-12-18 1993-08-11 Ciba Geigy Ag
FR2689124A1 (fr) * 1992-03-27 1993-10-01 Adir Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
EP0565296B1 (en) * 1992-04-07 1996-08-07 Neurim Pharmaceuticals (1991) Limited Use of melatonin for the manufacture of a medicament for the treatment of benign prostatic hyperplasia
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
IT1255199B (it) * 1992-07-01 1995-10-20 Franco Fraschini Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani
FR2696453B1 (fr) * 1992-10-02 1994-12-23 Adir Nouveaux arylalkyl(thio)amides, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.
US5403851A (en) * 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds

Also Published As

Publication number Publication date
FI963028A7 (fi) 1996-09-27
CA2182700A1 (en) 1995-10-12
WO1995027202A1 (en) 1995-10-12
HUT75128A (en) 1997-04-28
US5958683A (en) 1999-09-28
FI963028A0 (fi) 1996-07-31
MX9603966A (es) 1997-12-31
EP0753147A1 (en) 1997-01-15
US6218359B1 (en) 2001-04-17
HU9602670D0 (en) 1996-11-28
JPH09511334A (ja) 1997-11-11
AU2109695A (en) 1995-10-23

Similar Documents

Publication Publication Date Title
DE69421381D1 (de) Siebbelag für schwingsieb
ID21787A (id) Kerangka sandaran kursi
FI972318A0 (fi) Menetelmä ikkunan irrottamiseksi
EP0728442A3 (en) Capnometer
DE69628218D1 (de) Capnometer
DE69523119D1 (de) Bilderzeugungsverfahren
DE69517901D1 (de) Bilderzeugungsverfahren
DE69506240D1 (de) Bildschirm
FI963028A7 (fi) RZR-reseptoriperheen avulla suoritettava seulontamenetelmä
DE69518691D1 (de) Bilderzeugungsverfahren
ID20569A (id) Metode penyisipan gambar ganda
DE69424561D1 (de) Siebeinrichtung
FI971485A0 (fi) Sits
DE19581726T1 (de) Horizontal vibrierende Zentrifuge
DE69620071D1 (de) Siebvorrichtung
ATA186997A (de) Siebrechen
DE69629510D1 (de) Kapnometer
DE69431672D1 (de) Adrenergischer rezeptor
DE19781626T1 (de) Siebvorrichtung
NL194833B (nl) Schermconstructie.
BR9510060A (pt) Receptor
DE69523016D1 (de) Bilderzeugungsverfahren
ATA84697A (de) Siebrechen
ATA29894A (de) Siebwehr (grundwehr)
FI935770L (fi) Menetelmä varaustilanteen tutkimiseksi

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG